The material provided in this site is presented solely to improve public access to information about REVANCE. REVANCE will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. REVANCE will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site. REVANCE may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of REVANCE and affiliates to be materially different from those expected or anticipated in the forward-looking statements. REVANCE has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by REVANCE. The linked sites are not under control of REVANCE, and REVANCE disclaims any liability for all third party information and the use of it.
The contents of this site are owned and controlled by REVANCE. No use of any of these may be made without the prior written consent of REVANCE, except for personal, non-commercial purposes. All submissions communicated to REVANCE through this site shall be and remain REVANCE’s property.
January 19, 2018
Why this East Bay drug maker's stock price nearly doubled last year
January 18, 2018
Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'
January 16, 2018
New neuromodulators on the way to US market
January 11, 2018
Is RT002 de nieuwe botox?
December 27, 2017
RT002 Is a New Neuromodulator Injectable for Fine Lines
December 15, 2017
A ‘Better Botox’ May Target Millennials, Men and Hesitant Women
December 06, 2017
Revance Therapeutics: Sakura Success Should Worry Allergan
December 05, 2017
Could This Smaller Biotech Rival Allergan's Blockbuster Botox?
December 05, 2017
Beware Botox, a longer lasting wrinkle relaxer shows promise
December 05, 2017
This Botox Competitor Is on the Rise